According to a recent study, perceived stress can trigger the relapse of psoriatic skin lesions. The study was presented at the European Academy of Dermatology and Venereology Congress in Amsterdam (Sept. 27, 2024).
Home-based narrowband UV-B phototherapy for PsO as effective as office-based treatment
According to a recent study, home-based narrowband UV-B phototherapy for plaque and guttate psoriasis is as effective as office-based treatments.
Veterans are more at risk for psoriasis, skin cancer
According to a recent study, U.S. veterans are more likely to have a history of skin cancer, melanoma, and psoriasis when compared to non-veterans.
Extended guselkumab dosing effective for PsO super responders
According to a recent study, extending the dosing interval of guselkumab from eight weeks to sixteen weeks is non-inferior for treating moderate-to-severe psoriasis in super-responders.
PsO disease severity linked to missed work days
According to a recent study, patients with moderate-to-severe psoriasis are more than twice as likely to take a half-day off work than those with mild psoriasis.
Study suggests significant autoimmune disease prevalence in PsO patients
According to a recent study, there is a significant autoimmune disease prevalence in psoriasis patients.
Tildrakizumab efficacious in treating scalp psoriasis
According to a recent study, tildrakizumab was shown to be efficacious in treating moderate-to-severe plaque psoriasis on the scalp.
Topical treatment improves sleep quality in PsO, AD patients
According to a recent study, topical treatment decreases itch and improves sleep patterns in patients with psoriasis and atopic dermatitis.
Study finds link between skin disorder visibility and stigma
According to a recent study, the visibility of a skin disorder is directly linked to stigma including bullying.
Topical melatonin, rosuvastatin may reduce severity of mild-to-moderate plaque PsO
According to a recent study, topical melatonin and topical rosuvastatin were both effective in reducing the severity of mild-to-moderate plaque psoriasis.
